Hansa Medical to Host Conference Call to Provide First Quarter 2017 Business Update

On 26 April 2017, at 08:00 CET, Hansa Medical will publish its report for the first quarter of 2017. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 14:00 CET. The event will be hosted by Hansa Medical’s CEO and President, Göran Arvidson, and the presentation will be held in English.

Slides used in the presentation will be live on the company’s website during the call under Events & Webcast and will be made available after the call as well. To participate in the telephone conference, please call:

SE: +46 (0) 856 642 693
UK: +44 (0) 2030 089 803
US: +1 855 753 2236

A link to audio cast can be found on the Hansa Medical website under Events & Webcasts or here: https://tv.streamfabriken.com/hansa-medical-q1-2017 

For further information, please contact:
Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobil: +46707175477
E-mail: emanuel.bjorne@hansamedical.com

Göran Arvidson, President and CEO
Mobile: +4670633 3042
E-mail: goran.arvidson@hansamedical.com

Cord Communications, Stockholm
Mikael Widell
Mobile: +46 70 311 9960

Lars Wahlström
Mobile: +46 73 434 0771

FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody- degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in
other solid organ transplants and a wide range of acute autoimmune and oncology indications. The company also has a strong pipeline of preclinical assets that will provide a second wave of potential drugs as well as rights to royalties from the sales
of an innovative diagnostic assay for prediction of severe sepsis at emergency departments. Hansa Medical is based in Lund, Sweden, its shares share (ticker: HMED) are listed on Nasdaq Stockholm.


About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.